University of Exeter Medical School

Madhusubramanian Muthukumar

Madhusubramanian Muthukumar

Research Fellow in Modelling for Health Economics and Public Health

 M.Muthukumar@exeter.ac.uk

 South Cloisters 

 

South Cloisters, University of Exeter, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK

Overview

Madhusubramanian has a background in biotechnology and pursued masters in operational research and management science at Lancaster University. His interest in health economic modelling started with the dissertation work at Liverpool School of Tropical Medicine (LSTM), where he performed the discrete event simulation for modelling blood transfusion services in low- and middle-income countries. Over 6 years of experience across consulting and industry, he has led the development of economic evaluation of health care interventions including, but not limited to: cost effectiveness, budget impact and multi-criteria decision analysis (MCDA) models from conceptualisation to implementation across different disease areas such as Cervical dystonia, Asthma, Allergic rhinitis, Idiopathic pulmonary fibrosis, Schizophrenia and Bipolar mania.

In his current role as a Research Fellow in Modelling for Health Economics and Public health at PenTAG, Madhusubramanian undertakes the health technology assessment (HTA) of healthcare interventions, focusing especially on the critique of economic models for The National Institute for Health and Care Excellence (NICE).

Qualifications

  • Bachelor of Technology in Biotechnology (Hons.)
  • Master of Science in Operational Research and Management Science (Merit)

Research group links

Back to top

Research

Research interests

  • Health economic modelling
  • Health Technology Assessment
  • Methods for economic evaluation of healthcare interventions
  • Discrete event simulation

Research projects

  • NICE STA: Vamorolone for treating Duchenne muscular dystrophy
  • NICE EVA: Digital technologies to support the delivery of pulmonary rehabilitation for adults with COPD
  • NICE PATT: Renal cell carcinoma pathways pilot 
  • NICE STA: Tezepelumab for treating severe asthma
  • NICE HST: Setmelanotide for treating obesity caused by LEPR or POMC deficiency
  • NICE STA: Ozanimod for treating moderately to severely active ulcerative colitis
  • NICE HST: Givosiran for treating acute hepatic porphyria 
  • NICE STA: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 1 prior therapy 

Back to top

Publications

Journal articles

Igarashi A, Kaur H, Choubey A, Popli A, Muthukumar M, Yoshisue H, Funakubo M, Ohta K (2022). Cost-Effectiveness Analysis of Omalizumab for Severe Allergic Asthma in Japan Using Real-World Evidence. Value Health Reg Issues, 27, 41-48. Abstract.  Author URL.
Mtibaa M, Gupta S, Muthukumar M, Marvel J, Kaur H, Ishikawa R, Olivenstein R (2021). Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada. ClinicoEconomics and Outcomes Research, Volume 13, 957-967.
Muthukumar M, Desai K, Abogunrin S, Harrower T, Gabriel S, Dinet J (2017). Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom. Clinicoecon Outcomes Res, 9, 211-229. Abstract.  Author URL.

Conferences

Gupta S, Muthukumar M, Marvel J, Kaur H, Ishikawa R, Hasani I, Mtibaa M, Olivenstein R (2020). Cost-Effectiveness of Once-Daily Single-Inhaler Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma.
Muthukumar M, Kozawa M, Alvares L, Milligan K, Igarashi A (2018). Cost-effectiveness analysis of omalizumab compared with standard of care for severe allergic asthma based on real world evidence in Japan.
Corless S, Alvares L, Kumar P, Muthukumar M, Lesperance S, Katsaounou P (2018). Population health impact of omalizumab over 11 years of use in Ireland in moderate to severe allergic asthma.
Alvares L, Kumar M, Muthukumar M, Lesperance S, Katsaounou P (2017). PATIENT INPUT INTO VALUE ASSESSMENT OF RESPIRATORY MEDICINES: LESSONS LEARNED FROM VALUE FRAMEWORKS IN OTHER DISEASE AREAS.  Author URL.
Alvares L, Kumar P, Muthukumar M, Lesperance S, Katsaounou P (2017). Population Health Impact of Omalizumab over 15 Years of Experience in Moderate to Severe Allergic Asthma.
Desai K, Muthukumar M, Abogunrin S, Harrower T, Dinet J, Gabriel S (2015). Abobotulinumtoxin a in the management of cervical dystonia in the United Kingdom: a cost-effectiveness analysis.

Reports

Brand, A, O'Toole B, Muthukumar M, Matthews J, Kiff F, Shaw N, Wilson E, Digby-Bell J, Crathorne L, Melendez-Torres G, et al (2022). Ozanimod for treating moderately to severely active ulcerative colitis [ID3841]: a Single technology appraisal. NICE.
Farmer C, Brian O, Muthukumar M, Robinson S, Kiff F, Trigg L, Gardiner T, Newsome PN, Crathrone L, Melendez-Torres G, et al (2021). Givosiran for treating acute hepatic porphyria. [ID1549]: a Highly Specialised Technology Appraisal. NICE.
Barnish M, Brian O, Packman D, Muthukumar M, Matthews J, Shaw N, Rudin CE, Crathrone L, Melendez-Torres G (2021). Pembrolizumab for treating relapsed or. refractory classical Hodgkin’s lymphoma after. 1 or more multi-agent chemotherapy. regimens:. a Single Technology Appraisal. NICE.

Back to top

External Engagement and Impact

Awards and Honours

  • Summer Undergraduate Research Program (SURP) Fellowship (2009), Dr. B.R. Ambedkar Centre for Biomedical Research (ACBR), University of Delhi, India.
  • Robinson scholar of the year (2012/13), Department of Management science, Lancaster University Management School (LUMS), Lancaster University, UK.

Back to top

Edit Profile